HDAC3 and prostate carcinoma: In summary, the data presented by Yan et al (2018) define a mechanism‐based targeting of HDAC3 upstream of two key genomic altered pathways in prostate cancer and provide preclinical proof of principle to guide inhibitor development toward the clinic.